Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FOLLOWING THE NDA SUBMISSION FOR ICOTROKINRA TREATMENT OF ADULTS AND ADOLESCENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TO THE U.S. FDA IN JULY, THE EUROPEAN MEDICINES AGENCY (EMA) APPLICATION WAS SUBMITTED IN SEPTEMBER RUSFERTIDE GRANTED BREAKTHROUGH DESIGNATION FOR PATIENTS IN POLYCYTHEMIA VERA (PV) AND THE SUBJECT OF FOUR PRESENTATIONS INCLUDING 52-WEEK RESULTS OF THE VERIFY PHASE 3 STUDY AT ASH, THE 67TH ANNUAL AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING IN DECEMBER FIRST PATIENT DOSED IN THE PHASE 1 TRIAL OF PN-881, A FIRST-IN-CLASS ORAL IL-17 PEPTIDE ANTAGONIST IND-ENABLING STUDIES PROGRESSING AS PLANNED WITH TRIPLE-GLP/GIP/GCG AGONISTS PN-477SC AND PN-477O ORAL HEPCIDIN DEVELOPMENT CANDIDATE EXPECTED TO BE NOMINATED BY YEAR END CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $678.8 MILLION AS OF SEPTEMBER 30, 2025, ANTICIPATED TO PROVIDE CASH RUNWAY THROUGH AT LEAST END OF 2028 NEWARK, CA / ACCESS NEWSWIRE / NOVEMBER 6, 2025 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A CORPORATE UPDATE. "2025 CONTINUES TO BE A HIGHLY PRODUCTIVE YEAR WITH SIGNIFICANT ACCOMPLISHMENTS IN BOTH PARTNERED AND WHOLLY OWNED PROGRAMS," SAID DINESH V.

PROTAGONIST REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEWARK, CALIFORNIA / ACCESS NEWSWIRE / NOVEMBER 3, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") ANNOUNCED THAT CLINICAL DATA ON RUSFERTIDE IN POLYCYTHEMIA VERA, INCLUDING THE PHASE 3 VERIFY STUDY, WILL BE THE FOCUS OF FOUR PRESENTATIONS AT THE 67TH ANNUAL AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING BEING HELD IN ORLANDO, FLORIDA, FROM DECEMBER 6-9, 2025. ASH PRESENTATION DETAILS: PRESENTING AUTHOR: ANDREW KUYKENDALL, MD (MOFFITT CANCER CENTER) PUBLICATION NUMBER: 81 TITLE: RUSFERTIDE OR PLACEBO PLUS CURRENT STANDARD-OF-CARE THERAPY FOR POLYCYTHEMIA VERA: DURABILITY OF RESPONSE AND SAFETY RESULTS THROUGH WEEK 52 FROM THE RANDOMIZED CONTROLLED PHASE 3 VERIFY STUDY ORAL SESSION NAME: 634.

PROTAGONIST THERAPEUTICS ANNOUNCES ORAL AND POSTER PRESENTATIONS ON RUSFERTIDE AT THE 67TH ANNUAL ASH MEETING

NEWARK, CALIFORNIA / ACCESS NEWSWIRE / AUGUST 26, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

PROTAGONIST THERAPEUTICS TO PARTICIPATE IN MULTIPLE INVESTMENT BANK CONFERENCES IN SEPTEMBER 2025

NDA FOR ICOTROKINRA FOR THE TREATMENT OF ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PSO) SUBMITTED TO U.S. FDA IN JULY ANTHEM PHASE 2B TRIAL DATA OF ICOTROKINRA IN ULCERATIVE COLITIS SCHEDULED FOR AN ORAL PRESENTATION AT THE 33RD UNITED EUROPEAN GASTROENTEROLOGY WEEK (UEGW) ON OCTOBER 7TH PHASE 3 VERIFY TRIAL DATA SET OF RUSFERTIDE IN POLYCYTHEMIA VERA (PV) PRESENTED DURING PLENARY SESSION AT ASCO; U.S. NDA FILING ON TRACK FOR Q4 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $673.0 MILLION AS OF JUNE 30, 2025, ANTICIPATED TO PROVIDE CASH RUNWAY THROUGH AT LEAST END OF 2028 NEWARK, CA / ACCESS NEWSWIRE / AUGUST 6, 2025 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. "THUS FAR, 2025 HAS BEEN A YEAR OF BREAKTHROUGH ACCOMPLISHMENTS FOR PROTAGONIST, AS WE SAW RUSFERTIDE THE TOPIC OF THE PRESTIGIOUS ASCO PLENARY SESSION IN MAY, THE ANNOUNCEMENT OF AN ORAL AND INJECTABLE TRIPLE AGONIST ANTI-OBESITY PEPTIDE DEVELOPMENT CANDIDATE IN JUNE, AND MOST RECENTLY THE FIRST EVER NDA FILING OF ICOTROKINRA FOR PSORIASIS LAST MONTH," SAID DINESH V.

PROTAGONIST REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WEBCAST AND CONFERENCE CALL TO BE HELD ON MONDAY, JUNE 30TH AT 4:30 PM ET, DIAL IN INFORMATION BELOW NEWARK, CA / ACCESS NEWSWIRE / JUNE 26, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST TO ANNOUNCE ITS ORAL OBESITY DEVELOPMENT CANDIDATE AND TO SHARE IN VITRO AND PRE-CLINICAL PROOF-OF-CONCEPT STUDY RESULTS. CONFERENCE CALL AND WEBCAST DETAILS THE DIAL-IN NUMBERS FOR PROTAGONIST'S INVESTOR UPDATE ON MONDAY, JUNE 30TH AT 4:30 PM ET ARE: US-BASED INVESTORS: 1-877-407-0752INTERNATIONAL INVESTORS: 1-201-389-0912CONFERENCE CALL ID: 13754335 THE WEBCAST LINK FOR THE EVENT CAN BE FOUND HERE: HTTPS://VIAVID.WEBCASTS.COM/STARTHERE.JSP?EI=1724439&TP_KEY=584CDD1E86 A REPLAY OF THE PRESENTATION WILL BE AVAILABLE ON THE COMPANY'S INVESTOR RELATIONS EVENTS AND PRESENTATIONS WEBPAGE FOLLOWING THE EVENT.

PROTAGONIST THERAPEUTICS TO HOST CONFERENCE CALL TO ANNOUNCE AN ORAL OBESITY DEVELOPMENT CANDIDATE

NEWARK, CALIF. & OSAKA, JAPAN & CAMBRIDGE, MASS.--(BUSINESS WIRE)--PROTAGONIST THERAPEUTICS, INC. (PROTAGONIST) (NASDAQ:PTGX) AND TAKEDA (TSE:4502/NYSE:TAK) ANNOUNCED DETAILED RESULTS FROM THE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED VERIFY STUDY EVALUATING RUSFERTIDE IN PATIENTS WITH POLYCYTHEMIA VERA (PV), WHICH MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS. THE DATA WILL BE PRESENTED AS A LATE-BREAKING ORAL PRESENTATION AT THE 61ST AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETI.

PROTAGONIST AND TAKEDA ANNOUNCE ASCO PLENARY PRESENTATION HIGHLIGHTING FULL 32-WEEK RESULTS FROM PHASE 3 VERIFY STUDY OF RUSFERTIDE, SHOWING REDUCTIONS IN PHLEBOTOMY, IMPROVED HEMATOCRIT CONTROL IN POLYCYTHEMIA VERA

NEWARK, CA / ACCESS NEWSWIRE / MAY 21, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") TODAY ANNOUNCED THAT DINESH V. PATEL, PH.D.

PROTAGONIST THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE 2025

POSITIVE TOP LINE RESULTS FROM RUSFERTIDE PHASE 3 VERIFY TRIAL IN POLYCYTHEMIA VERA (PV) ANNOUNCED; FULL DATA SELECTED FOR ORAL PRESENTATION DURING PLENARY SESSION AT ASCO ON JUNE 1ST CONFERENCE CALL TO BE HELD JUNE 2ND AT 8AM EDT TO DISCUSS RUSFERTIDE DATA PRESENTED AT ASCO FULL DATASET FROM PHASE 3 ICONIC-LEAD TRIAL WITH ICOTROKINRA IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS (PSO) PRESENTED AT THE 2025 AAD MEETING IN MARCH; DATA FROM ADOLESCENT SUBSET PRESENTED AT WORLD CONGRESS OF PEDIATRIC DERMATOLOGY IN APRIL POSITIVE TOP LINE RESULTS FROM ICOTROKINRA PHASE 2B ANTHEM TRIAL IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) ANNOUNCED IN MARCH, DATA TO BE PRESENTED AT MEDICAL CONFERENCE LATER IN 2025 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $697.9 MILLION AS OF MARCH 31, 2025, ANTICIPATED TO PROVIDE CASH RUNWAY THROUGH AT LEAST END OF 2028 NEWARK, CALIFORNIA / ACCESS NEWSWIRE / MAY 6, 2025 / PROTAGONIST THERAPEUTICS (NASDAQ:PTGX) ("PROTAGONIST" OR "THE COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE. "PROTAGONIST IS OFF TO A VERY STRONG 2025 WITH MULTIPLE TRANSFORMATIONAL EVENTS IN THE FIRST QUARTER FOR OUR TWO LATE-STAGE PARTNERED ASSETS, RUSFERTIDE AND ICOTROKINRA WHICH ARE PROGRESSING TO NDA FILINGS BY YEAR END," SAID DINESH V.

PROTAGONIST REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEWARK, CA / ACCESS NEWSWIRE / APRIL 23, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY") ANNOUNCED THAT AN ABSTRACT WAS ACCEPTED FOR PRESENTATION AT THE PLENARY SESSION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING BEING HELD MAY 30 - JUNE 3, 2025. PRESENTATION DETAILS: PRESENTING AUTHOR: ANDREW T.

PROTAGONIST THERAPEUTICS ANNOUNCES PLENARY PRESENTATION ON VERIFY PHASE 3 STUDY WITH RUSFERTIDE AT ASCO 2025

NEWARK, CA / ACCESS NEWSWIRE / APRIL 16, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF PEPTIDE-BASED THERAPEUTICS, TODAY ANNOUNCED THAT ON APRIL 15, 2025 (THE "GRANT DATE"), IT ISSUED AN EQUITY INDUCEMENT AWARD TO A NEW EMPLOYEE UPON HIS COMMENCEMENT OF EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH THE TERMS OF HIS EMPLOYMENT OFFER LETTER. THE AWARD WAS GRANTED UNDER THE COMPANY'S AMENDED AND RESTATED 2018 INDUCEMENT PLAN, WHICH WAS ADOPTED ON MAY 29, 2018, AND AMENDED ON FEBRUARY 18, 2020 AND FEBRUARY 15, 2022.

PROTAGONIST THERAPEUTICS REPORTS GRANTING OF INDUCEMENT AWARD

PAST WINNERS INCLUDE WAYMO, NVIDIA, DUOLINGO, AND NOVO NORDISK, AMONG OTHERS NEWARK, CA / ACCESS NEWSWIRE / MARCH 18, 2025 / PROTAGONIST THERAPEUTICS, INC. ("PROTAGONIST" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE DISCOVERY AND DEVELOPMENT OF PEPTIDE-BASED THERAPEUTICS, TODAY ANNOUNCED ITS INCLUSION IN FAST COMPANY'S PRESTIGIOUS ANNUAL LIST OF THE WORLD'S MOST INNOVATIVE COMPANIES FOR 2025. FAST COMPANY'S ANNUAL LIST OF THE WORLD'S MOST INNOVATIVE COMPANIES SPOTLIGHTS ORGANIZATIONS ACROSS VARIOUS INDUSTRIES THAT ARE DRIVING MEANINGFUL CHANGE THROUGH GROUNDBREAKING IDEAS AND TRANSFORMATIVE TECHNOLOGIES.

PROTAGONIST THERAPEUTICS NAMED TO FAST COMPANY'S ANNUAL LIST OF THE WORLD'S MOST INNOVATIVE COMPANIES OF 2025

NEWARK, CALIF. & OSAKA, JAPAN & CAMBRIDGE, MASS.--(BUSINESS WIRE)--PROTAGONIST THERAPEUTICS, INC. (PROTAGONIST) (NASDAQ:PTGX) AND TAKEDA (TSE:4502/NYSE:TAK) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FOR THE PHASE 3 VERIFY STUDY, IN WHICH PHLEBOTOMY-DEPENDENT PATIENTS WITH POLYCYTHEMIA VERA (PV) WERE RANDOMIZED TO TREATMENT WITH EITHER RUSFERTIDE OR PLACEBO, AS AN ADD-ON TO STANDARD OF CARE TREATMENT. THE STUDY MET ITS PRIMARY ENDPOINT AND ALL FOUR KEY SECONDARY ENDPOINTS. RUSFERTIDE IS A FIRST.

Protagonist Therapeutics, Inc.

PTGX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Protagonist Therapeutics, Inc.

PTGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PTGX